AbstractBackground: Glioblastomamultiforme (GBM) is an aggressive and fatal brain tumor that presents significant challenges in treatment. Conventional chemoradiation therapy has been the standard approach, but hypofractionated radiation therapy combined with temozolomide offers an alternative with potential benefits in efficacy and safety.
Objective: This study evaluates and compares the therapeutic outcomes and safety profiles of hypofractionated radiation therapy with temozolomide versus conventional chemoradiation in patients diagnosed with GBM.
Methods: A cohort of GBM patients was retrospectively analyzed to assess the clinical outcomes of the two treatment protocols. Parameters such as overall survival, progression-free survival, and adverse effects were reviewed. Statistical tools were employed to evaluate differences in efficacy and safety between the two approaches.
Results: Patients treated with hypofractionated radiation therapy combined with temozolomide exhibited comparable overall survival rates to those receiving conventional chemoradiation, with a significant reduction in treatment duration and adverse effects. Progression-free survival also demonstrated similar outcomes across both treatment protocols.
Conclusion: Hypofractionated radiation therapy with temozolomide is a promising alternative to conventional chemoradiation for GBM patients, offering comparable efficacy while potentially reducing the burden of side effects and treatment duration.
